We've had a big year here at Transcriptic. Here's a look back at some data points on what the year looked like for us.
As we head towards the end of 2017, inquiries about 2018 intern opportunities are already ramping up. I thought it would be interesting to have one of our recent interns write about his experiences. If you're starting your hunt, whether at Transcriptic or elsewhere, here's a little bit of what you might expect:
Five year, $10 million+ deal with robotic cloud lab will double Ginkgo’s foundry output; increase scale of its synthetic biology innovation
BOSTON & MENLO PARK, CALIF., Oct. 3, 2017 -- Ginkgo Bioworks, the organism company, today announced a collaboration with robotic cloud laboratory Transcriptic. Through a five year agreement valued at more than $10 million, Ginkgo will incorporate Transcriptic’s cutting-edge robotic automation software into its Boston-based foundries. The combined technologies will bolster Ginkgo’s automation capabilities and engineering capacity, strengthening its platform and cementing a foundation for continued growth.
Tune into our upcoming thought leadership webinar, “How the Internet of Things is Disrupting Science” on Thursday 24th August at 4pm UK / 11am EST / 8am PST. Even if you can't attend live, a recording of the webinar will be sent to all registrants afterward.
Mesoscale Discovery (MSD) Sector S 600 integrated with the Transcriptic robotic cloud lab
The Transcriptic robotic cloud lab provides a great advantage for large-scale biomarker assays, delivering consistent sample to sample processing with robotic reliability, all on demand when you need it. We’ve enabled both large pharma and small biotech to quantify DNA, RNA and proteins from hundreds or thousands of samples in an automated and programmatically driven way.
The cloud lab model of Transcriptic ensures that the lab automation is used to its highest efficiency, this is enabled by having the robotic infrastructure as a shared resource consumed by all users. A result of this is that once runs are submitted they enter into a queue until enough robotic capacity is available for execution.
Part of growing Transcriptic means making industry leading protocols and reagents accessible to our users. For this reason I’m happy to announce that on November 4 2016 Agilent Technologies’ QuikChange Lightning, site-directed mutagenesis kit will be available in the Transcriptic protocol browser.
Since the start of Transcriptic users have only been able to conduct Biosafety Level 1 (BSL-1) experiments on our automated cloud infrastructure. We believed that executing well at this lower stringency threshold meant that we could deliver a great service for our users whilst still ensuring we could rapidly develop our capabilities.